Core Insights - Genelux Corporation (NASDAQ: GNLX) is preparing for a significant milestone in the upcoming year, with topline results expected from its phase 3 OnPrime/GOG-3076 registrational study for the oncolytic immunotherapy drug Olvi-Vec [2] Company Overview - Genelux Corporation is focused on developing innovative cancer therapies, particularly through its oncolytic immunotherapy approach [2] Investment Analysis - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks [2]

Core Insights - Genelux Corporation has initiated the Phase 2 (VIRO-25) trial for Olvi-Vec in recurrent non-small cell lung cancer (NSCLC) patients who have failed previous treatments, marking a significant milestone for patients with limited options [1][2] - The trial aims to evaluate the efficacy and safety of Olvi-Vec combined with platinum-doublet chemotherapy and a physician's choice of immune checkpoint inhibitor (ICI) compared to docetaxel [2] - Interim results from the trial are expected to be available by mid-2025 [1][2] Company Overview - Genelux Corporation is a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive solid tumors [4] - The company's lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus, currently being evaluated in multiple clinical trials, including a Phase 3 trial for platinum-resistant ovarian cancer [4] - Olvi-Vec has been administered to over 150 patients across seven clinical trials, demonstrating a generally well-tolerated safety profile and evidence of clinical benefit [3] Product Details - Olvi-Vec is a proprietary oncolytic vaccinia virus with a large engineering capacity, designed to infect and kill various tumor cell types while eliciting an anti-tumor immune response [3] - The ongoing Phase 1b/2 trial for intravenous delivery of Olvi-Vec in recurrent small cell lung cancer is co-sponsored with Newsoara Biopharma Co. Ltd., highlighting the potential of Olvi-Vec as a systemically administered treatment option [2]

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024. Mr. Zindrick will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Re ...

Core Insights - Genelux Corporation, a late clinical-stage immuno-oncology company, will present its clinical-stage programs and upcoming milestones at the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024 [1][2] Company Overview - Genelux is focused on developing next-generation oncolytic immunotherapies for patients with aggressive and difficult-to-treat solid tumors [4] - The company's leading product candidate, Olvi-Vec, is a modified strain of the vaccinia virus currently in a Phase 3 trial for platinum-resistant/refractory ovarian cancer [4] - Olvi-Vec is being evaluated in a multicenter, randomized, open-label trial comparing its efficacy and safety in combination with platinum-doublet and bevacizumab against physician's choice of chemotherapy and bevacizumab [4] - The company utilizes its proprietary CHOICE™ platform to develop a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [4] Conference Details - Thomas Zindrick, President, Chairman, and CEO of Genelux, will engage in a fireside chat scheduled for September 11, 2024, at 12:30 p.m. ET [2] - The conference will also include virtual one-on-one meetings for institutional investors interested in discussing with Genelux management [3]

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024. The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 12:00 p.m. ET on Tuesday, August 6, 2024. ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology co ...

Company Overview - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [5] - The company's leading product candidate, Olvi-Vec, is a modified strain of the vaccinia virus currently undergoing a Phase 3 trial for platinum-resistant/refractory ovarian cancer [5] Public Offering Details - Genelux has initiated an underwritten public offering of its common stock and accompanying warrants, with the expectation to grant underwriters a 30-day option to purchase an additional 15% of the shares sold [1][2] - Guggenheim Securities is the sole book-running manager, while Newbridge Securities Corporation acts as co-manager for the offering [2] Regulatory Compliance - The shares are being offered under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC), and the offering will be conducted via a written prospectus [3]

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in conne ...

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.   "Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Looking ahead, we are excited about advancing Olvi-Vec into additional c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 001-41599 77-0583529 Commissi ...